Patents by Inventor Stefan Müllner
Stefan Müllner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10060911Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.Type: GrantFiled: August 18, 2012Date of Patent: August 28, 2018Assignee: Protagen AktiengesellschaftInventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
-
Patent number: 10036746Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.Type: GrantFiled: January 12, 2017Date of Patent: July 31, 2018Assignee: PROTAGEN AGInventors: Heike Göhler, Petra Rengers, Angelika Lüking, Stefan Müllner
-
Publication number: 20170115288Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.Type: ApplicationFiled: January 12, 2017Publication date: April 27, 2017Inventors: Heike Göhler, Petra Rengers, Angelika LÜKING, Stefan MÜLLNER
-
Patent number: 9588115Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.Type: GrantFiled: March 28, 2014Date of Patent: March 7, 2017Assignee: PROTAGEN AGInventors: Heike Göhler, Petra Rengers, Angelika Lüking, Stefan Müllner
-
Publication number: 20160054318Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.Type: ApplicationFiled: March 28, 2014Publication date: February 25, 2016Inventors: Heike GÖHLER, Petra RENGWRS, Angelika LÜKING, Stefan MÜLLNER
-
Publication number: 20140309133Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterisation and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.Type: ApplicationFiled: August 18, 2012Publication date: October 16, 2014Applicant: Protagen AktinegesellschaftInventors: Stefan Müllner, Peter Schulz-Knappe, Angelika Lueking, Heike Göhler, Jessica Schwermann
-
Publication number: 20130303395Abstract: The invention relates to novel marker sequences for systemic lupus erythematosus and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for systemic lupus erythematosus diseases using said marker sequences. The invention further relates to a diagnostic device containing such marker sequences for systemic lupus erythematosus, especially to a protein biochip and the use thereof.Type: ApplicationFiled: October 12, 2011Publication date: November 14, 2013Applicant: PROTAGEN AKTIENGESELLSCHAFTInventors: Angelika Lueking, Axel Kowald, Stefan Müllner, Christian Scheer, Matthias Schneider
-
Publication number: 20130029864Abstract: The invention relates to novel marker sequences for Alzheimer's disease, in particular Alzheimer's dementia, and their diagnostic use including a screening method in order to identify potential drugs for the treatment/prophylaxis of Alzheimer's disease by means of the said novel marker sequences. Moreover, the invention relates to a diagnostic device comprising said novel marker sequences for diagnosing Alzheimer's disease, particularly a protein array (chip) and its use hereto.Type: ApplicationFiled: October 1, 2010Publication date: January 31, 2013Applicant: PROTAGEN AktiengesellschaftInventors: Angelika Lueking, Stefan Müllner, Charlotte Teunissen, Jens Wiltfang
-
Publication number: 20100331201Abstract: The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or differential screening of suitable protein binders in native and non-native form.Type: ApplicationFiled: June 11, 2007Publication date: December 30, 2010Applicant: PROTAGEN AktiengesellschaftInventors: Stefan Müllner, Angelika Lüking, Verena Trappe
-
Publication number: 20080160091Abstract: An oral and dental hygiene product is comprised of a composite material comprising calcium salts which are slightly soluble in water, in the form of nanoparticulate primary particles having a length of from 5 to 150 nm and a cross section of from 2 to 50 nm and protein components selected from the group consisting of proteins, protein hydrolysates and protein hydrolysate derivatives, and 0.1 to 9% by weight of a cleaning agent based on the total weight of the product.Type: ApplicationFiled: September 28, 2007Publication date: July 3, 2008Applicant: HENKEL KOMMANDITGESELLSCHAFT AUF AKTIENInventors: Christian KROPF, Marcel ROTH, Ulrike BRUENINGHAUS, Stefan MUELLNER, Albrecht WEISS, Ulrich SCHOERKEN, Lothar KINTRUP, Burkhard ESCHEN, Amerigo PASTURA, Peter WUELKNITZ, Ruediger KNIEP, Hans LASKA, Michael MEINDERS, Hans DOLHAINE
-
Publication number: 20050202476Abstract: The invention relates kits for detecting microorganisms containing at least one oligonucleotide for at least one species or a group of species of microorganisms which occur on the skin and to methods using the kits according to the invention.Type: ApplicationFiled: January 18, 2005Publication date: September 15, 2005Inventors: Andrea Saettler, Claudia Jassoy, Regine Scholtyssek, Vera Maienschein, Silke Nieveler, Albrecht Weiss, Karl-Heinz Trebesius, Claudia Beimfohr, Wolfgang Ludwig, Richard Bamberg, Karl-Heinz Schleifer, Stefan Muellner, Ingrid Bergmaier
-
Publication number: 20050202477Abstract: The present invention describes oligonucleotides for detecting microorganisms, and processes and kits including the same.Type: ApplicationFiled: January 18, 2005Publication date: September 15, 2005Inventors: Andrea Saettler, Claudia Jassoy, Regine Scholtyssek, Vera Maienschein, Silke Nieveler, Albrecht Weiss, Karl-Heinz Trebesius, Claudia Beimfohr, Wolfgang Ludwig, Richard Bamberg, Karl-Heinz Schleifer, Stefan Muellner, Ingrid Bergmaier
-
Publication number: 20040152772Abstract: Provided is a group of active substances capable of inhibiting the proliferation of cancer cells and inhibiting inflammation, as well as suppressing bodily defense reactions to control autoimmune diseases, transplant rejections, and acute and chronic inflammatory reactions.Type: ApplicationFiled: March 15, 2004Publication date: August 5, 2004Inventors: Erich Eigenbrodt, Stefan Muellner, Sybille Mazurek, Hugo Fasold
-
Patent number: 6589785Abstract: A method for disrupting frozen cells and/or tissue in a solid, frozen state in the presence of a solid denaturing substance is provided. The method comprises providing frozen cells and/or tissue in frozen solid form, adding thereto the solid denaturing substance in sold form, and applying mechanical force thereto for disruption of the frozen cells and/or tissue. The frozen cells and/or tissue include muscle cells and/or muscle tissue, wheat cells and/or wheat tissue, and maize cells and/or maize tissue. Further, the solid, denaturing substance in solid form is a crystalline substance and can be selected from urea, thiourea, guanidium chloride, guanidium thiocyanate and ammonium sulfate. Also the solid, denaturing substance in solid form is added to the frozen cells and/or tissue in frozen form in an approximately 1 to 20 fold (w/w) excess.Type: GrantFiled: July 31, 2000Date of Patent: July 8, 2003Assignee: Aventis Research & Technologies GmbH & Co KGInventors: Stefan Müllner, Thomas Neumann
-
Patent number: 6582691Abstract: The invention relates to an insect cell vector for the production of proteins from the DEAD protein family.Type: GrantFiled: September 29, 2000Date of Patent: June 24, 2003Assignee: Aventis Research & Technologies GmbH & Co.Inventors: Karl-Christian Gallert, Stefan Müllner, Christoph Hüls, Britta Böhnisch
-
Patent number: 6403299Abstract: The present invention relates to the identification and molecular-biological and biochemical characterization of novel DEAH-box proteins which show structural similarity with other known helicases. The invention also relates to DNA sequences encoding such proteins. It is demonstrated that such proteins bind ATP and nucleic acid and possess helicase and ATPase activities. This invention further relates to processes for preparation of such proteins and their use in pharmacologically relevant test systems and therapeutic applications.Type: GrantFiled: September 11, 2000Date of Patent: June 11, 2002Assignee: Aventis Research & Technologies GmbH & Co. KGInventors: Bernd Kirschbaum, Stefan Muellner, Robert Bartlett
-
Patent number: 6337325Abstract: A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases.Type: GrantFiled: July 20, 1999Date of Patent: January 8, 2002Assignee: Hoechst AktiengesellschaftInventors: Martin Schönharting, Stefan Müllner, Peter Zabel
-
Patent number: 6265588Abstract: A compound of the formula where R1 is the radical of the formula II or III is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.Type: GrantFiled: May 30, 2000Date of Patent: July 24, 2001Assignee: Aventis Pharma Deutschland GmbHInventors: Stefan Müllner, Bernd Kirschbaum, Wilfried Schwab
-
Patent number: 6251645Abstract: The present invention relates to the identification and molecular-biological and biochemical characterization of novel DEAH-box proteins which show structural similarity with other known helicases. The invention also relates to DNA sequences encoding such proteins. It is demonstrated that such proteins bind ATP and nucleic acid and possess helicase and ATPase activities. This invention further relates to processes for preparation of such proteins and their use in pharmacologically relevant test systems and therapeutic applications.Type: GrantFiled: June 23, 1999Date of Patent: June 26, 2001Assignee: Aventis Research & Technologies GmbH & Co. KGInventors: Bernd Kirschbaum, Stefan Muellner, Robert Bartlett
-
Patent number: 5942429Abstract: The present invention relates to the identification and molecular-biological and biochemical characterization of novel DEAH-box proteins which show structural similarity with other known helicases. The invention also relates to DNA sequences encoding such proteins. It is demonstrated that such proteins bind ATP and nucleic acid and possess helicase and ATPase activities. This invention further relates to processes for preparation of such proteins and their use in pharmacologically relevant test systems and therapeutic applications.Type: GrantFiled: December 4, 1996Date of Patent: August 24, 1999Assignee: Aventis Research & Technologies GmbH & Co KG.Inventors: Bernd Kirschbaum, Stefan Muellner, Robert Bartlett